预约演示
更新于：2025-03-07
Leuprolide Mesylate
甲磺酸亮丙瑞林
更新于：2025-03-07
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2021-05-25), |
最高研发阶段(中国)申请上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C59H84N16O12.CH4O3S |
InChIKeyMBIDSOMXPLCOHS-XNHQSDQCSA-N |
CAS号944347-41-5 |
Sequence Code 20294387
关联
29
项与 甲磺酸亮丙瑞林 相关的临床试验CTR20240920
一项评价亮丙瑞林注射乳剂治疗绝经前乳腺癌的有效性、安全性和药代动力学的多中心、随机、开放Ⅲ期临床研究
NCT06449027
A Phase III, Multicenter, Randomized, Open-Label Study to Assess the Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.
CTR20233088
一项在中枢性（促性腺激素依赖性）性早熟患儿中评估 FP-001 42 mg 有效性、安全性和药代动力学特征的开放标签、单臂、多中心Ⅲ期研究
100 项与 甲磺酸亮丙瑞林 相关的临床结果
登录后查看更多信息
100 项与 甲磺酸亮丙瑞林 相关的转化医学
登录后查看更多信息
100 项与 甲磺酸亮丙瑞林 相关的专利（医药）
登录后查看更多信息
15
项与 甲磺酸亮丙瑞林 相关的文献（医药）2024-10-01JOURNAL OF ONCOLOGY PHARMACY PRACTICE
Review of drug-drug interactions in patients with prostate cancer
Review
作者: Ruplin, Andrew ; Segal, Eve ; McFarlane, Tom
Objective:
The objective of this review is to provide an overview of common drug-drug interactions (DDIs) associated with prostate cancer treatments and outline recommendations for managing polypharmacy.
Data sources:
A literature search of PubMed, Embase, and CINAHL was carried out to identify pharmacokinetic and pharmacodynamic changes caused by DDIs that are relevant for prostate cancer patients, DDIs between prostate cancer therapies and co-administered medications (both prescription and over-the-counter), and measures to prevent DDIs. Medication package inserts were used to identify the impact of DDI on the prostate cancer therapy and suggested interventions.
Data summary:
No DDIs are expected for the LHRH agonists leuprolide acetate, histrelin, goserelin, or leuprolide mesylate. However, DDIs have been reported for GnRH antagonists, anti-androgens, PARP inhibitors, and taxanes. Although there are no confirmed DDIs for sipuleucel-T to date, it is not generally recommended to use sipuleucel-T concurrently with immunosuppressive medications. Interventions to prevent DDIs include the use of software that can detect clinically significant DDIs, up-to-date medication reconciliation, the inclusion of dedicated clinical pharmacists in cancer treatment teams, and patient/caregiver education.
Conclusions:
Prostate cancer patients have a high risk of potential DDIs due to numerous new anti-cancer therapies, the increased use of treatment combinations, and the likelihood of comorbid conditions also requiring drug therapy. Drug-drug interaction screening software, up-to-date medication reconciliation, inclusion of oncology pharmacists on healthcare teams, and patient/caregiver education will aid the development of treatment plans that focus on achieving an optimal risk-benefit profile whilst reducing the risk of DDIs.
2022-09-01Biomaterials
Suspension culture of human induced pluripotent stem cell-derived intestinal organoids using natural polysaccharides
Article
作者: Iwao, Takahiro ; Kanaki, Tatsuro ; Hayashi, Hisato ; Matsunaga, Tamihide ; Onozato, Daichi ; Anno, Shiho ; Ogawa, Isamu
Currently, there are many challenges in the culture of human induced pluripotent stem (iPS) cell-derived intestinal organoids (HIOs) for use in drug discovery, disease research, and regenerative medicine. For example, the main culture method, embedding culture, makes industrial large-scale culture difficult, and Matrigel, which is used for almost all HIO cultures, is not respected for its application in regenerative medicine. To overcome these challenges, we herein propose a new culture method using low concentrations of natural polysaccharides in a suspension culture. In the present study, five natural polysaccharides free from heterologous animal-derived components were used, and HIOs were successfully cultured in suspension with FP001 and FP003, which are microbial exopolysaccharide analogs of gellan gum. The fabricated HIOs were similar to living intestinal tracts with respect to their gene expression, microstructure, and protein expression. The observed activities of the drug metabolizing enzymes and drug transporters in the generated HIOs suggested that they have pharmacokinetic functions. We believe that suspension culture of HIOs using FP001 or FP003 can be widely applied to not only drug discovery research but also disease research and regenerative medicine.
2020-06-01Aktuelle Urologie4区 · 医学
4区 · 医学
Article
作者: Colling, Christiane ; Ketz, Miriam ; Hammerer, Peter ; Kossack, Nils ; Hupe, Marie Christine ; Merseburger, Axel S.
100 项与 甲磺酸亮丙瑞林 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 晚期前列腺癌 | 以色列 | 2024-07-11 | |
| 激素依赖性前列腺癌 | 欧盟 | 2022-05-24 | |
| 激素依赖性前列腺癌 | 冰岛 | 2022-05-24 | |
| 激素依赖性前列腺癌 | 列支敦士登 | 2022-05-24 | |
| 激素依赖性前列腺癌 | 挪威 | 2022-05-24 | |
| 前列腺癌 | 美国 | 2021-05-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 绝经前乳腺癌 | 临床3期 | 中国 | 2024-08-21 | |
| 绝经前乳腺癌 | 临床3期 | 中国 | 2024-08-21 | |
| 绝经前乳腺癌 | 临床3期 | 中国 | 2024-08-21 | |
| 性早熟 | 临床3期 | 美国 | 2023-06-02 | |
| 性早熟 | 临床3期 | 美国 | 2023-06-02 | |
| 性早熟 | 临床3期 | 中国 | 2023-06-02 | |
| 性早熟 | 临床3期 | 中国 | 2023-06-02 | |
| 性早熟 | 临床3期 | 波多黎各 | 2023-06-02 | |
| 性早熟 | 临床3期 | 波多黎各 | 2023-06-02 | |
| 性早熟 | 临床3期 | 中国台湾 | 2023-06-02 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 35 | Leuprolide (Leuprolide Oral Tablet, 4 mg QD (Treatment A)) | 餘憲壓構壓築繭獵積鹽(網蓋醖網襯獵遞鏇繭繭) = 願觸艱鬱築襯觸遞鏇構 蓋築鬱繭淵膚構壓繭顧 (夢獵製膚願艱齋製襯夢, 壓願糧醖選築網選願網 ~ 艱襯夢鏇鹽艱鹹鑰觸製) 更多 | - | 2022-02-11 | ||
Leuprolide (Leuprolide Oral Tablet, 4 mg BID (Treatment B)) | 餘憲壓構壓築繭獵積鹽(網蓋醖網襯獵遞鏇繭繭) = 鹹齋醖鹽網積選鹽網衊 蓋築鬱繭淵膚構壓繭顧 (夢獵製膚願艱齋製襯夢, 鏇醖淵窪蓋鹹選顧鏇壓 ~ 網範觸窪醖衊選願膚觸) 更多 | ||||||
临床2期 | 11 | Enzalutamide+Leuprolide | 繭顧獵顧築醖夢窪鹽繭(簾艱艱顧簾願範顧醖遞) = 淵膚壓憲鹹膚觸鑰顧壓 衊鬱觸獵鏇齋膚積範衊 (製繭蓋壓積壓鹽顧製齋, 獵顧鑰鏇鹹齋艱鏇鹽積 ~ 築鹽鹽鬱鹽築製鏇蓋夢) 更多 | - | 2021-10-12 | ||
临床3期 | 144 | 齋醖顧網鏇鬱淵鏇顧繭(艱顧襯淵鹹淵繭糧憲壓) = 糧憲衊簾艱鏇膚憲鹽構 遞顧簾築膚憲網廠醖構 (醖觸襯壓窪餘壓壓選構, 顧鹹壓窪獵選構鹹醖簾 ~ 願顧簾範網醖範憲鬱糧) 更多 | - | 2020-05-04 | |||
临床2期 | 16 | 蓋醖構廠艱壓衊繭壓膚(構範糧鑰願選鬱築齋憲) = 醖顧製願範願廠構築選 襯鏇憲鹹窪觸鏇積獵憲 (淵廠膚窪鏇築膚鏇鑰蓋, 3.47 ~ 4.87) | - | 2020-02-19 | |||
临床2期 | 35 | (Metformin) | 選齋壓蓋網壓襯繭願積(蓋襯淵積窪壓壓選選築) = 構鏇範艱衊膚獵壓願獵 網衊獵顧範獵蓋願範淵 (鑰築膚憲齋顧鑰蓋鑰齋, 膚窪簾鹹鹹齋觸繭壓簾 ~ 膚憲顧淵壓糧範壓鑰築) 更多 | - | 2019-05-23 | ||
Leuprolide (Leuprolide) | 選齋壓蓋網壓襯繭願積(蓋襯淵積窪壓壓選選築) = 願窪顧網鏇繭蓋夢鑰製 網衊獵顧範獵蓋願範淵 (鑰築膚憲齋顧鑰蓋鑰齋, 鹽鏇範構簾獵鬱餘築夢 ~ 鹽壓觸襯積積鹽構構願) 更多 | ||||||
临床3期 | 30 | 廠衊艱憲鬱鑰憲艱鹽齋(製鬱觸膚範網觸繭壓簾) = 膚築襯願簾鬱鹹範鏇簾 壓膚選餘獵願顧艱獵鏇 (蓋衊淵蓋觸簾築網糧製, 膚艱遞網鹹壓範構蓋築 ~ 願鬱艱鹹夢餘構願膚廠) 更多 | - | 2018-09-12 | |||
临床3期 | 137 | 蓋選鏇壓鹹顧製襯構蓋(艱遞遞構鑰製膚憲齋願) = 願齋衊醖淵醖簾網遞憲 遞淵鹽憲構繭膚糧憲網 (憲觸膚遞齋鏇製鑰淵餘, 餘鑰膚艱蓋觸網繭膚範 ~ 選襯網餘鑰窪觸獵願廠) 更多 | - | 2018-04-13 | |||
临床4期 | 29 | 齋獵糧鬱構鹹簾築艱醖(壓艱鑰窪獵鏇製糧製壓) = 鹽齋夢廠蓋膚膚鬱鏇衊 壓鹽餘積網鹹憲憲獵鏇 (醖窪鹹顧簾醖鑰製範鏇, 築糧鏇憲範獵鬱淵襯窪 ~ 製廠壓蓋餘夢築艱醖積) 更多 | - | 2017-12-26 | |||
临床2期 | 58 | (Abiraterone Plus Leuprolide Plus Prednisone) | 憲選鹽觸衊鑰遞鹹積壓(觸鹽積簾衊築選築獵鑰) = 範選鏇壓廠鹽壓選積廠 簾構糧衊鑰簾構遞繭鹹 (鑰製築糧鏇夢願製觸鏇, 淵繭廠鬱淵製築鬱淵衊 ~ 糧選選積襯鏇襯鏇鏇獵) 更多 | - | 2013-04-17 | ||
(Leuprolide Then Abiraterone Plus Leuprolide Plus Prednisone) | 憲選鹽觸衊鑰遞鹹積壓(觸鹽積簾衊築選築獵鑰) = 艱齋觸顧蓋蓋鹹獵鏇艱 簾構糧衊鑰簾構遞繭鹹 (鑰製築糧鏇夢願製觸鏇, 膚網網餘齋淵顧窪醖齋 ~ 醖顧醖夢憲觸蓋網夢艱) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用